Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 28 publications
Roflumilast foam versus vehicle foam for seborrheic dermatitis (STRATUM clinical study): a plain language summary.
Journal: The Journal of dermatological treatment
Published: June 11, 2026
Long-term treatment of atopic dermatitis with roflumilast cream 0.15% in patients aged 6 years or older (INTEGUMENT-OLE clinical study): a plain language summary.
Journal: The Journal of dermatological treatment
Published: June 11, 2026
Long-Term Safety and Efficacy of Once-Daily and Proactive Twice-Weekly Roflumilast Cream 0.05% for Mild-to-Moderate Atopic Dermatitis in Children Aged 2-5 Years From a 52-Week, Phase 3 Trial (INTEGUMENT-OLE).
Journal: Pediatric dermatology
Published: September 25, 2025
Roflumilast Cream 0.3% in Patients with Chronic Plaque Psoriasis: Pooled PASI and PASI-HD Results from the DERMIS Phase III Trials.
Journal: Dermatology and therapy
Published: July 29, 2025
Early Evidence of Safety, Clinical Benefit, and Pharmacokinetics of Roflumilast Cream 0.3% Once Daily for Treatment of Mild or Moderate Plaque Psoriasis in Children Aged 2-11 Years.
Journal: Pediatric dermatology
Published: May 10, 2025
Long-Term Safety and Efficacy of Roflumilast Foam 0.3% in Patients with Seborrheic Dermatitis: A Phase II, Open-Label Trial of up to 52 Weeks.
Journal: American journal of clinical dermatology
Published: April 07, 2025
Long-Term Safety and Efficacy with Roflumilast Cream 0.15% in Patients Aged ≥6 Years with Atopic Dermatitis: A Phase 3 Open-Label Extension Trial.
Journal: Dermatitis : contact, atopic, occupational, drug
Published: January 10, 2025
Assessment of the Vehicle for Roflumilast Cream Compared to a Ceramide-Containing Moisturizing Cream in Mild Eczema.
Journal: Journal of drugs in dermatology : JDD
Published: October 03, 2024
Efficacy and Safety of Once-Daily Roflumilast Cream 0.05% in Pediatric Patients Aged 2-5 Years With Mild-to-Moderate Atopic Dermatitis (INTEGUMENT-PED): A Phase 3 Randomized Controlled Trial.
Journal: Pediatric dermatology
Published: October 01, 2024
Roflumilast Cream, 0.15%, for Atopic Dermatitis in Adults and Children: INTEGUMENT-1 and INTEGUMENT-2 Randomized Clinical Trials.
Journal: JAMA dermatology
Published: September 18, 2024
Tape-strip profiling identifies unique immune and lipid dysregulation in patients with seborrheic dermatitis.
Journal: Journal of the American Academy of Dermatology
Published: September 11, 2024
Last Updated: 09/26/2026